000141402 001__ 141402
000141402 005__ 20240229105126.0
000141402 0247_ $$2doi$$a10.1182/bloodadvances.2017013334
000141402 0247_ $$2pmid$$apmid:29344579
000141402 0247_ $$2pmc$$apmc:PMC5761630
000141402 0247_ $$2ISSN$$a2473-9529
000141402 0247_ $$2ISSN$$a2473-9537
000141402 0247_ $$2ISSN$$a2476-9537
000141402 0247_ $$2altmetric$$aaltmetric:31027097
000141402 037__ $$aDKFZ-2018-01908
000141402 041__ $$aeng
000141402 082__ $$a610
000141402 1001_ $$aMerz, Maximilian$$b0
000141402 245__ $$aPrognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.
000141402 260__ $$aWashington, DC$$bAmerican Society of Hematology$$c2018
000141402 3367_ $$2DRIVER$$aarticle
000141402 3367_ $$2DataCite$$aOutput Types/Journal article
000141402 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1542801336_24033
000141402 3367_ $$2BibTeX$$aARTICLE
000141402 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141402 3367_ $$00$$2EndNote$$aJournal Article
000141402 520__ $$aWe investigated subclonal cytogenetic aberrations (CA) detected by interphase fluorescence in situ hybridization (iFISH) in patients with newly diagnosed multiple myeloma (MM) enrolled in the Haemato Oncology Foundation for Adults in the Netherlands (HOVON)-65/German-Speaking MM Group (GMMG)-HD4 phase 3 trial. Patients were either treated with 3 cycles of vincristine, Adriamycin, and dexamethasone or bortezomib, Adriamycin, and dexamethasone and then thalidomide or bortezomib maintenance after tandem autologous transplantation. Subclones were defined either by presence of different copy numbers of the same chromosome loci and/or CA present in at least 30% less and maximally 2/3 of cells compared with the main clone CA. Patients with subclones harbored more frequently high risk (31.0%) or hyperdiploid main clone aberrations (24.8%) than patients with t(11;14) in the main clone (10.1%). Gains and deletions of c-MYC were the only CA that occurred more frequently as subclone (8.1%/20.5%) than main clone (6.2%/3.9%, respectively). Treatment with bortezomib completely overcame the negative prognosis of high-risk CA in patients without subclones, but not in patients with additional subclonal CA. High-risk patients treated without bortezomib showed dismal outcome whether subclones were present or not. Cytogenetic heterogeneity defined by subclonal CA is of major prognostic significance in newly diagnosed MM patients treated with bortezomib within the HOVON-65/GMMG-HD4 trial.
000141402 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000141402 588__ $$aDataset connected to CrossRef, PubMed,
000141402 7001_ $$aJauch, Anna$$b1
000141402 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b2$$udkfz
000141402 7001_ $$aBochtler, Tilmann$$b3
000141402 7001_ $$aSchönland, Stefan Olaf$$b4
000141402 7001_ $$aSeckinger, Anja$$b5
000141402 7001_ $$aHose, Dirk$$b6
000141402 7001_ $$aBertsch, Uta$$b7
000141402 7001_ $$aNeben, Kai$$b8
000141402 7001_ $$0P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3$$aRaab, Marc Steffen$$b9$$udkfz
000141402 7001_ $$aHillengass, Jens$$b10
000141402 7001_ $$aSalwender, Hans$$b11
000141402 7001_ $$aBlau, Igor Wolfgang$$b12
000141402 7001_ $$aLindemann, Hans-Walter$$b13
000141402 7001_ $$aSchmidt-Wolf, Ingo G H$$b14
000141402 7001_ $$aScheid, Christof$$b15
000141402 7001_ $$aHaenel, Mathias$$b16
000141402 7001_ $$aWeisel, Katja C$$b17
000141402 7001_ $$aGoldschmidt, Hartmut$$b18
000141402 773__ $$0PERI:(DE-600)2876449-3$$a10.1182/bloodadvances.2017013334$$gVol. 2, no. 1, p. 1 - 9$$n1$$p1 - 9$$tBlood advances$$v2$$x2473-9537$$y2018
000141402 909CO $$ooai:inrepo02.dkfz.de:141402$$pVDB
000141402 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000141402 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000141402 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000141402 9141_ $$y2018
000141402 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141402 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000141402 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141402 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index
000141402 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141402 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000141402 9201_ $$0I:(DE-He78)G170-20160331$$kG170$$lExperimentelle Therapien hämatologischer Neoplasien$$x1
000141402 980__ $$ajournal
000141402 980__ $$aVDB
000141402 980__ $$aI:(DE-He78)C060-20160331
000141402 980__ $$aI:(DE-He78)G170-20160331
000141402 980__ $$aUNRESTRICTED